对，期待治疗，它是B细胞淋巴去质因子，抑制B细胞的，其实我们在靶向治疗

Yes, looking forward to treatment. It is a B-cell lymphoblastic factor that inhibits B-cells. In fact, we use a lot of targeted therapy. Before belyumumab, we have very rich experience in using rituximab. So we are still very sure about the effect of targeted drugs, so this is the same, but it is selective targeting, and that is CD20 antibody. This is also a relative inhibition point on B cells, so based on this we think it is Provides a very new perspective.

Yes, look forward to treatment, it is B cell lymphocyte degenerative factor, inhibit B cells, in fact, we use a lot of targeted treatment, in the Bellevue monoantigen before we have a very rich experience with ritoxicy monoantigen, so we are still very sure of the effect of targeted drugs, so this is the same, but only selective targeting, that is CD20 antibodies, this is also a relative B cell inhibition point, so based on this we think it is a very new perspective.

Yes, we are looking forward to treatment. It is a B-cell lymphadenectomy factor that inhibits B cells. In fact, we used rituximab very much in targeted therapy. Before baileyumab, we had rich experience in using rituximab, so we are very sure of the effect of targeted drugs. So this is the same, but it is only selective targeting, that is, CD20 antibody, which is also relative So based on this, we think it provides a very new perspective.<br>